Athens Research & Technology, Inc., a leading manufacturer of native human and animal proteins for the life sciences industry, today announced it has rebranded as Athens Bioscience, Inc. The name change coincides with the launch of a redesigned e-commerce website, expanded global distribution capabilities, and the introduction of industry-first analytical quality standards for protein Certificates of Analysis.
Founded in 1986 at the University of Georgia, the company has spent four decades specializing in the isolation and purification of native proteins from human and animal sources. Its products are used by IVD manufacturers, cell culture media companies, pharmaceutical researchers, and academic institutions worldwide, and have been cited in more than 2,300 peer-reviewed publications.
“Over the past four decades, our work has expanded well beyond research reagents,” said John Mitchell, Chief Executive Officer of Athens Bioscience. “Today, our proteins are built into commercial diagnostic kits, cell culture media formulations, and calibrator and control products used by manufacturers on five continents. The name ‘Research & Technology’ no longer reflects the full scope of what we do—or what our customers need us to do next. Athens Bioscience better captures where we’re headed: a global protein manufacturer that serves the entire life sciences value chain, from early discovery through commercial production.”
The company emphasized that its core operations remain unchanged. All manufacturing continues at the company’s facility in Athens, Georgia, under an ISO 9001:2015 certified quality management system. Existing catalog numbers, lot reservation agreements, and open purchase orders will be honored without interruption, and the same scientific team continues to lead protein purification and quality control.
New Website and Enhanced Quality Standards
The new Athens Bioscience website has been redesigned to allow customers to search by research area and application—not just by protein name—so IVD manufacturers can quickly identify assay-grade reagents while cell culture scientists can filter for proteins with validated bioactivity data. Technical documents, SDS-PAGE gel images, and Certificates of Analysis are accessible directly from each product page.
Alongside the rebrand, the company has introduced new analytical quality standards for its protein products. Every new production lot now ships with a Certificate of Analysis that includes lot-specific SDS-PAGE gel images with quantitative densitometry—providing measured purity values tied to the customer’s specific lot rather than generic representative images. For immunogen-grade products, the company now provides LC-MS/MS compositional analysis performed on a high-resolution Orbitrap platform, identifying every detectable protein in the sample and its relative abundance.
“This rebrand reflects a company that has built something rare in our industry—four decades of specialized manufacturing expertise paired with advanced analytical capabilities that deliver our customers real confidence in product quality,” said Benjamin Newland, Chairman of the Board of Athens Bioscience. “The decision to provide lot-specific analytical data on every high-purity product is a meaningful step for the industry. It provides unprecedented transparency for purchasers, and it raises the bar for quality documentation across our sector. As a board, we see this as the foundation for Athens Bioscience’s next chapter of growth.”
Global Distribution Expansion
Athens Bioscience has also expanded its international footprint through its distributor program. Partnerships with regional distributors across the European Union, United Kingdom, China, and other key markets now enable customers to source Athens proteins through local procurement platforms with local-language support. The company plans to grow its distributor network to more than 40 active partners by the end of 2026.
“We’ve spent four decades earning our reputation one lot at a time,” Mitchell added. “The new name and the new platform are designed to make it easier for customers to access the same quality—wherever they are, whatever their application.”
About Athens Bioscience
Athens Bioscience, Inc. (formerly Athens Research & Technology, Inc.) manufactures native human and animal proteins for the global life sciences industry. Founded in 1986 and headquartered in Athens, Georgia, the company serves IVD manufacturers, cell culture media companies, pharmaceutical researchers, and academic institutions worldwide. For more information, visit www.athensbioscience.com.